GO:1903672 positive regulation of sprouting angiogenesis: Signaling Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903672 describes any process that activates or increases the frequency, rate or extent of sprouting angiogenesis, the formation of new blood vessels from pre-existing ones.
• Sprouting angiogenesis is driven by endothelial cell activation, tip/stalk cell specification, basement membrane degradation, migration, proliferation and lumen formation.
• Key positive regulators include VEGFR2 signaling, Notch pathway components, angiopoietin-2, von Willebrand factor, OPN3, DLC1 and HMGB1 [1,4,5,7,8].
• Ischemia and oxidative stress are potent physiological triggers of positive regulation of sprouting angiogenesis [2,3].
• Dysregulated positive regulation of sprouting angiogenesis contributes to tumor growth, endometriosis, angiodysplasia and ischemic disease [4,7,8].
• CRISPR knockout, point mutation, knock-in and overexpression models enable causal dissection of genes that positively regulate sprouting angiogenesis [1,4,5,7].
Description
GO:1903672, positive regulation of sprouting angiogenesis, is a Gene Ontology biological process term that captures any process which activates or increases the frequency, rate or extent of sprouting angiogenesis. Sprouting angiogenesis is the predominant mechanism by which new capillaries arise from pre-existing vessels during development, wound healing and ischemia-driven neovascularization [3,6]. Because this process is tightly controlled by pro- and anti-angiogenic signals, its positive regulation is central to both physiological vessel growth and pathological angiogenesis in cancer, endometriosis and vascular malformations [4,7,8]. Researchers study GO:1903672 to identify the molecular switches that tip the balance toward vessel sprouting, and to evaluate how genetic or pharmacological perturbation of these switches alters endothelial cell behavior [1,5,8]. The term is therefore a focal point for vascular biology, oncology and regenerative medicine.
positive regulation of sprouting angiogenesis At A Glance
| GO ID | GO:1903672 |
|---|---|
| GO term | positive regulation of sprouting angiogenesis |
| Ontology | biological_process |
| Synonym | activation of sprouting angiogenesis; up regulation of sprouting angiogenesis; up-regulation of sprouting angiogenesis; upregulation of sprouting angiogenesis |
| Definition | Any process that activates or increases the frequency, rate or extent of sprouting angiogenesis. |
| Major function | Enhances the formation of new capillary sprouts from pre-existing blood vessels. |
| Related process | Sprouting angiogenesis (GO:0002040) and regulation of sprouting angiogenesis (GO:1903671). |
| Biological context | Development, wound healing, ischemia, tumor angiogenesis and endometriosis. |
| Research relevance | Target for pro- or anti-angiogenic therapy and for CRISPR-based functional genomics. |
What Is GO:1903672?
In plain terms, GO:1903672 refers to any biological process that turns up or accelerates sprouting angiogenesis. It is a child of the broader regulation of sprouting angiogenesis and encompasses molecular events such as increased VEGFR2 signaling, enhanced endothelial tip cell formation, elevated extracellular matrix remodeling and stimulated endothelial proliferation and migration that collectively raise the frequency, rate or extent of new sprout formation [1,4,6].
Why Is positive regulation of sprouting angiogenesis Important in Cell Biology?
Positive regulation of sprouting angiogenesis is important because it determines whether tissues receive adequate oxygen and nutrients, and because its excessive activation drives diseases such as cancer, endometriosis and angiodysplasia [4,7,8]. Conversely, insufficient positive regulation contributes to ischemia and impaired wound healing. Understanding the genes and signals that positively regulate sprouting angiogenesis therefore informs both anti-angiogenic cancer therapy and pro-angiogenic strategies for ischemic disease [1,3,8].
• Controls oxygen and nutrient delivery during development and tissue repair.
• Is activated by ischemia and oxidative stress to restore perfusion [2,3].
• Is co-opted by tumors to sustain growth and metastasis.
• Contributes to the pathogenesis of endometriotic lesions through Notch signaling.
• Is impaired in von Willebrand factor deficiency, linking hemostasis to angiogenesis.
• Provides targets for anti-angiogenic drugs and pro-angiogenic therapeutics [1,8].
• Involves endothelial tip/stalk cell specification and VEGFR2 signaling [1,6].
• Can be studied with CRISPR knockout, knock-in and overexpression models [1,4,5,7].
• Serves as a readout for endothelial cell function in HUVEC and in vivo assays [1,4].
• Links extracellular matrix remodeling to endothelial migration and proliferation [5,6].
What Happens During positive regulation of sprouting angiogenesis?
Endothelial cell activation and tip/stalk specification
In simple terms: Endothelial cells receive pro-angiogenic signals and some become leaders (tip cells) while others become followers (stalk cells).
Positive regulation of sprouting angiogenesis begins when pro-angiogenic factors such as VEGF activate endothelial cells, leading to the selection of tip cells that extend filopodia and guide the sprout, and stalk cells that proliferate to elongate the vessel. Notch signaling modulates this specification, and its control is required for proper sprouting of endometriotic lesions. OPN3 positively regulates angiogenesis in HUVECs through interaction with VEGFR2, illustrating how membrane receptors can amplify the activation step.
Basement membrane degradation and extracellular matrix remodeling
In simple terms: The vessel wall is loosened so endothelial cells can migrate out.
Activated endothelial cells secrete proteases that degrade the basement membrane, allowing sprout emergence. Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process, indicating that DLC1 supports matrix and cytoskeletal events required for sprouting. This step is a point where positive regulation can be enhanced or blocked.
Endothelial migration and proliferation
In simple terms: Endothelial cells move and multiply to build the new vessel.
Tip cells migrate toward angiogenic cues while stalk cells proliferate. Positive regulation increases the frequency and rate of these events. HMGB1 enforces tumor angiogenesis through autocrine regulation, showing that tumor-derived factors can sustain endothelial migration and proliferation. Ischemia-driven angiogenesis also depends on these migratory and proliferative responses.
Lumen formation and perfusion
In simple terms: The new sprout hollows out and connects to the circulation.
Once the sprout extends, endothelial cells reorganize to form a lumen and anastomose with neighboring vessels, restoring blood flow. Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2, linking hemostatic proteins to lumen stability and gut angiodysplasia. This final step determines whether positive regulation translates into functional perfusion.
Integration with oxidative and ischemic signals
In simple terms: Low oxygen and oxidative stress can turn up sprouting.
Oxidative stress-induced angiogenesis and ischemia-driven angiogenesis are physiological contexts in which positive regulation of sprouting angiogenesis is activated [2,3]. These signals converge on endothelial transcriptional programs that increase sprout frequency and rate, making them relevant to ischemic disease and tumor biology [2,3,8].
Key Genes Involved in GO:1903672 positive regulation of sprouting angiogenesis
The following genes and proteins have been experimentally linked to positive regulation of sprouting angiogenesis in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFR2 (KDR) | Receptor for VEGF; activates endothelial sprouting | Target for OPN3 interaction studies and angiogenesis assays |
| OPN3 | Positively regulates angiogenesis via VEGFR2 interaction | Knockout or overexpression in HUVECs to test sprouting |
| Notch receptors (NOTCH1-4) | Control tip/stalk cell specification | Modulate sprouting in endometriotic lesions |
| DLC1 | Supports endothelial angiogenesis process | Down-regulation compromises angiogenesis |
| HMGB1 | Autocrine factor enforcing tumor angiogenesis | Tumor angiogenesis models |
| Angiopoietin-2 (ANGPT2) | Mediates angiogenesis impairment in VWF deficiency | Gut angiodysplasia models |
| Von Willebrand factor (VWF) | Hemostatic protein influencing angiogenesis | Deficiency impairs angiogenesis via ANGPT2 |
| VEGFA | Primary pro-angiogenic ligand | Ischemia and tumor angiogenesis studies [3,8] |
| HIF1A | Oxygen-sensing transcription factor | Ischemia-driven angiogenesis |
| NOS3 (eNOS) | Nitric oxide production in endothelium | Oxidative stress-induced angiogenesis |
| CDH5 (VE-cadherin) | Endothelial junctional adhesion | Endothelial sprouting and lumen formation |
| PECAM1 (CD31) | Endothelial cell adhesion and signaling | Endothelial identity and sprouting assays |
| ACTA2 | Pericyte/smooth muscle coverage | Vessel maturation in angiogenesis models |
| COL4A1 | Basement membrane component | Matrix remodeling during sprouting |
| MMP2 | Matrix metalloproteinase | Basement membrane degradation in sprouting |
| MMP9 | Matrix metalloproteinase | ECM remodeling during angiogenesis |
| CXCR4 | Chemokine receptor on endothelial tip cells | Guidance of sprouting vessels |
| NRP1 | VEGF co-receptor | Tip cell guidance and sprouting |
How Is positive regulation of sprouting angiogenesis Regulated?
Positive regulation of sprouting angiogenesis is controlled by a balance of pro-angiogenic and anti-angiogenic signals. VEGFR2 activation by VEGF is a central positive input, and OPN3 can enhance this axis through direct interaction with VEGFR2. Notch signaling provides lateral inhibition that restricts tip cell numbers, and its modulation affects sprouting in endometriotic lesions. DLC1 down-regulation compromises angiogenesis, indicating that DLC1 is required for normal positive regulation. HMGB1 acts as an autocrine amplifier of tumor angiogenesis. Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2, revealing crosstalk between hemostasis and angiogenic regulation. Ischemia and oxidative stress provide environmental inputs that increase sprouting [2,3].
positive regulation of sprouting angiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGB1 | Tumor angiogenesis | Tumor xenograft with HMGB1 knockout or overexpression |
| NOTCH1-4 | Endometriosis | Endometriotic lesion models with Notch modulation |
| DLC1 | Cancer angiogenesis | Endothelial DLC1 knockdown or knockout |
| VWF / ANGPT2 | Gut angiodysplasia | VWF-deficient mouse models |
| OPN3 / VEGFR2 | Angiogenesis regulation | HUVEC knockout and overexpression |
Cancer and tumor angiogenesis
Tumors co-opt positive regulation of sprouting angiogenesis to build a vascular supply. HMGB1 enforces tumor angiogenesis through autocrine regulation, and targeting this pathway may reduce tumor perfusion. DLC1 down-regulation in endothelial cells compromises angiogenesis, suggesting that loss of endothelial DLC1 could alter tumor vessel sprouting.
Endometriosis
Notch signaling controls sprouting angiogenesis of endometriotic lesions, and dysregulated positive regulation contributes to lesion vascularization. This makes sprouting angiogenesis a candidate target for endometriosis therapy.
Ischemic and oxidative stress-related disease
Ischemia-driven angiogenesis and oxidative stress-induced angiogenesis are adaptive responses that depend on positive regulation of sprouting angiogenesis [2,3]. In ischemic tissues, enhancing this process could improve reperfusion, whereas in oxidative stress-related pathology, excessive sprouting may be harmful [2,3].
Gut angiodysplasia and von Willebrand factor deficiency
Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2, with relevance for gut angiodysplasia. This links a hemostatic disorder to defective positive regulation of sprouting angiogenesis.
From positive regulation of sprouting angiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is OPN3 required for endothelial sprouting? | OPN3 knockout HUVECs |
| Does a point mutation in VEGFR2 alter sprouting? | VEGFR2 point-mutation knock-in endothelial cells |
| Can DLC1 rescue angiogenesis defects? | DLC1 knock-in or overexpression in endothelial cells |
| How does Notch modulation affect endometriotic sprouting? | Notch gain- and loss-of-function in lesion models |
| Does HMGB1 drive tumor angiogenesis? | HMGB1 knockout or overexpression in tumor models |
| Is ANGPT2 required for VWF-related angiogenesis impairment? | ANGPT2 knockout in VWF-deficient models |
How to Study the positive regulation of sprouting angiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Endothelial sprouting assay | Frequency and rate of sprout formation | Testing pro-angiogenic genes in HUVECs [1,5] |
| Co-immunoprecipitation | Protein-protein interaction | OPN3-VEGFR2 interaction |
| Notch reporter assay | Notch signaling activity | Endometriotic lesion sprouting |
| Ischemia model | Angiogenesis in ischemic tissue | Ischemia-driven angiogenesis |
| Tumor xenograft | Tumor angiogenesis | HMGB1 autocrine regulation |
| VWF-deficient model | Angiogenesis impairment | Gut angiodysplasia |
| Oxidative stress assay | ROS-induced angiogenesis | Oxidative stress-induced angiogenesis |
| Gene expression profiling | Transcriptional changes | Endothelial response to pro-angiogenic cues |
Endothelial sprouting assays
In vitro sprouting assays using HUVECs or other endothelial cells measure the frequency and rate of sprout formation under pro-angiogenic stimulation [1,5]. These assays are used to test whether a gene positively regulates sprouting angiogenesis [1,5].
In vivo angiogenesis models
Ischemia-driven and tumor angiogenesis models allow assessment of sprouting in a physiological context [3,8]. Endometriotic lesion models and VWF-deficient models provide disease-specific readouts [4,7].
Molecular interaction and signaling assays
Co-immunoprecipitation and proximity assays can detect interactions such as OPN3 with VEGFR2. Notch signaling activity can be monitored with reporter assays in lesion models.
Oxidative stress and hypoxia experiments
Oxidative stress-induced angiogenesis and ischemia-driven angiogenesis can be modeled with hypoxia or ROS exposure to test positive regulation [2,3].
How CRISPR Can Be Used to Study GO:1903672 positive regulation of sprouting angiogenesis
Knockout
CRISPR knockout of candidate genes such as OPN3, DLC1 or HMGB1 in endothelial or tumor cells can test whether they are required for positive regulation of sprouting angiogenesis [1,5,8]. Loss-of-function phenotypes in sprouting assays provide causal evidence [1,5].
Point Mutation
Point mutations can be introduced into receptors such as VEGFR2 to dissect signaling residues that mediate positive regulation. This approach helps distinguish catalytic or binding requirements from scaffold functions.
Knock-in
Knock-in of tagged or mutant alleles allows tracking of proteins like Notch receptors or DLC1 during sprouting [4,5]. Tagged knock-ins enable imaging of protein localization in endothelial tip cells [4,5].
Overexpression
Overexpression of pro-angiogenic factors such as HMGB1 or OPN3 can enhance sprouting and model pathological angiogenesis [1,8]. This is useful for testing sufficiency in positive regulation [1,8].
How EDITGENE Supports positive regulation of sprouting angiogenesis Research
Researchers studying positive regulation of sprouting angiogenesis-related genes often need to determine whether a candidate gene is causally involved in endothelial sprouting or is merely correlated with it. EDITGENE provides CRISPR-based cell models and screening services to establish causality and mechanism.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of sprouting angiogenesis research.
Frequently Asked Questions About positive regulation of sprouting angiogenesis
What is GO:1903672 positive regulation of sprouting angiogenesis?
GO:1903672 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of sprouting angiogenesis.
What genes are involved in positive regulation of sprouting angiogenesis?
Genes include VEGFR2, OPN3, Notch receptors, DLC1, HMGB1, ANGPT2 and VWF, among others [1,4,5,7,8].
How is sprouting angiogenesis positively regulated?
It is positively regulated by pro-angiogenic signals such as VEGF-VEGFR2, Notch modulation, HMGB1 autocrine signaling and environmental cues like ischemia and oxidative stress [1,2,3,4,8].
What diseases involve positive regulation of sprouting angiogenesis?
Cancer, endometriosis, ischemic disease and gut angiodysplasia involve dysregulated positive regulation of sprouting angiogenesis [3,4,7,8].
What is the role of Notch signaling in sprouting angiogenesis?
Notch signaling controls sprouting angiogenesis of endometriotic lesions and helps specify tip and stalk cells.
How does OPN3 regulate angiogenesis?
OPN3 positively regulates angiogenesis in HUVECs through interaction with VEGFR2.
What is the role of DLC1 in angiogenesis?
Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.
How does von Willebrand factor affect angiogenesis?
Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2, relevant for gut angiodysplasia.
Can CRISPR be used to study positive regulation of sprouting angiogenesis?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can test causal roles of genes in sprouting angiogenesis [1,4,5,7,8].
What assays measure sprouting angiogenesis?
Endothelial sprouting assays, ischemia models, tumor xenografts and VWF-deficient models are commonly used [1,3,7,8].
Conclusion
GO:1903672 positive regulation of sprouting angiogenesis is a central biological process that governs new blood vessel formation in development, repair and disease. The cited literature identifies key positive regulators such as OPN3, Notch, DLC1, HMGB1, ANGPT2 and VWF, and links their activity to cancer, endometriosis, ischemia and angiodysplasia [1,4,5,7,8]. CRISPR-based models provide a rigorous path to establish causality and to develop therapeutic strategies that either promote or inhibit sprouting angiogenesis [1,4,5,7,8].
References
- 1. Luo H et al.. 2025. OPN3-mediated positive regulation of angiogenesis in HUVECs through VEGFR2 interaction.. Commun Biol 8(1):529 PMID: 40164822
- 2. Huang YJ et al.. 2019. Oxidative stress-induced angiogenesis.. J Clin Neurosci 63:13-16 PMID: 30837109
- 3. Dor Y et al.. 1997. Ischemia-driven angiogenesis.. Trends Cardiovasc Med 7(8):289-94 PMID: 21235898
- 4. Körbel C et al.. 2018. Notch signaling controls sprouting angiogenesis of endometriotic lesions.. Angiogenesis 21(1):37-46 PMID: 28993956
- 5. Shih YP et al.. 2017. Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.. Cancer Lett 398:46-51 PMID: 28408355
- 6. Patan S. 2004. Vasculogenesis and angiogenesis.. Cancer Treat Res 117:3-32 PMID: 15015550
- 7. Constantinescu-Bercu A et al.. 2026. Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia.. Blood 147(21):2541-2553 PMID: 41587100
- 8. van Beijnum JR et al.. 2013. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1.. Oncogene 32(3):363-74 PMID: 22391561
